Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Council’s Action Plan for FY2013 Calls for Conducting 10 Kinds of Clinical Trials within 5 Years
July 9, 2012
- On-Site Strategy Consultations to Be Held in Kansai Region: MHLW
July 6, 2012
- Interest Shown in Development of 3 Unapproved Drugs/Indications Including Metyrosine
July 6, 2012
- PMDA to Use Science Committee to Help Strengthen Review System: Executive Director Utsumi
July 5, 2012
- MHLW Approves 2 APIs Including Switch OTC Version of Allegra
July 5, 2012
- New Bar Code Labeling Rules to Take Effect for Oral, Topical Drugs from July 2015
July 3, 2012
- 18 Ethical APIs/35 Products Reported at PAC
July 3, 2012
- MHLW Approves 15 Products Including Inlyta and Tenelia
July 2, 2012
- Mandatory Generic Drug Use Still Impractical Due to People’s Lingering Distrust: MHLW
July 2, 2012
- MHLW Calls for Caution to Secondary Damage from Fainting After HPV Vaccination
June 29, 2012
- MHLW Proposes 2-Stage Discussions on Cost-Effective Assessment of Medical Technologies
June 29, 2012
- JPO Rules Actonel Patent Invalid; Ajinomoto Considering Appeal
June 29, 2012
- MHLW Talks to Drug Makers with Facilities Eligible for Exemption from Planned Power Outages
June 27, 2012
- Targets for Generic Drug Use Should Be Included in Medical Expenditure Optimization Plan: Mr Konishi of DPJ
June 26, 2012
- MHLW Orders Updates from Chugai Following Criticism for Reporting Deficiencies by Roche in US
June 26, 2012
- MHLW Approves 11 Products Including Additional Indication for Lyrica
June 26, 2012
- Median Review Time Down by About Half Since FY2007: PMDA
June 25, 2012
- Antipyretic/Analgesics Are Most Common Cause for Relief Benefits for Damage from ADRs: PMDA
June 25, 2012
- PMDA Adopts New Rule for Staff Re-Employment Effective This Month, No Uses Made Yet
June 25, 2012
- 166 Applications Received for Preliminary Interviews for Regulatory Strategy Consultation in First 9 Months: PMDA
June 25, 2012
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…